Vemurafenib and Radiosensitization

• Autores: Lise Boussemart, Catherine Boivin, Joël Claveau, Yun Gan Tao
• Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 149, Nº. 7, 2013, págs. 855-857
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Importance The BRAF inhibitor, vemurafenib, was recently approved for the treatment of patients with BRAFV600 metastatic melanoma. Wider use of this drug and longer follow-up periods of treatment are resulting in the emergence of a growing number of reports detailing new adverse effects. Cutaneous adverse effects are preeminent with UV-A�dependent phototoxicity, hyperkeratotic folliculitis, hand-foot skin reaction, hair changes, verrucous papillomas, keratoacanthomas, and squamous cell carcinomas.